Publish in this journal
Journal Information
Vol. 71. Issue 10.
Pages 878 (October 2018)
Vol. 71. Issue 10.
Pages 878 (October 2018)
Letter to the Editor
Full text access
Management of Anticoagulants in Procedures That Can Cause Bleeding
Manejo de anticoagulantes en procedimientos que pueden producir una hemorragia
Enrique Martín-Rioboóa, Cristina Martín-Mañerob, Paula Medina-Duránc, Luis Angel Pérula-de Torresa,d,
Corresponding author

Corresponding author:
a Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
b Unidad de Gestión Clínica Ribera del Muelle, Servicio Andaluz de Salud, Puerto Real, Cádiz, Spain
c Unidad de Gestión Clínica Poniente, Servicio Andaluz de Salud, Córdoba, Spain
d Unidad Docente de Medicina Familiar y Comunitaria de Córdoba, Servicio Andaluz de Salud, Córdoba, Spain
Related content
David Vivas, Inmaculada Roldán, Raquel Ferrandis, Francisco Marín, Vanessa Roldán, Antonio Tello-Montoliu, Juan Miguel Ruiz-Nodar, Juan José Gómez-Doblas, Alfonso Martín, Juan Vicente Llau, María José Ramos-Gallo, Rafael Muñoz, Juan Ignacio Arcelus, Francisco Leyva, Fernando Alberca, Raquel Oliva, Ana María Gómez, Carmen Montero, Fuat Arikan, Luis Ley, Enrique Santos-Bueso, Elena Figuero, Antonio Bujaldón, José Urbano, Rafael Otero, Juan Francisco Hermida, Isabel Egocheaga, José Luis Llisterri, José María Lobos, Ainhoa Serrano, Olga Madridano, José Luis Ferreiro
David Vivas, Jose Luis Ferreiro, Inmaculada Roldán
This item has received
Article information
Full Text
Download PDF
Full Text
To the Editor,

Vivas et al.1 are to be congratulated on their article; reaching a consensus among 24 scientific societies is a notable achievement.

We have read the article carefully, and while we agree with almost all its content, a review of the literature2–9 reveals some areas of concern. One major concern is the limited information on bridging therapy with lowmolecular-weight heparin (LMWH). Aside from stipulating that heparin bridging should be restricted to diseases associated with a high thromboembolic risk, the consensus document barely discusses LMWH. For example, there is no mention of the appropriate LMWH dose for patients at high thromboembolic risk (equivalent to 1mg/kg/12h enoxaparin, or 1.5mg/kg if a single dose is used2–4). Moreover, we were confused by the following sentences: “The last dose of LMWH should be administered 12hours before the operation or procedure in the case of prophylactic doses and 24hours in the case of therapeutic doses. Unfractionated heparin should be administered 4 to 6hours in advance.” This implies the existence of distinct prophylactic and therapeutic doses; however, we were unable to find any other reference to prophylactic and therapeutic doses in the text. This generates doubts about what course of action should be adopted. Similarly, the article does not specify when postprocedure LMWH should be initiated or how long the treatment should be maintained.

A second major concern relates to which patients should be maintained on anticoagulation therapy. Table 1 Table 1 of the supplementary material lists the low-risk procedures that do not require suspension of anticoagulation, corresponding to the assignation “a” in Figure 2 Figure 2 of the main text. The problem is that this assignation applies to very few patients, thus giving the impression that some hospital specialties have been over cautious in emphasizing the remote risk of bleeding and a thromboembolic episode.

For example, the text specifically mentions pulmonary vein catheter ablation, but this is not reflected in the supplementary material, where this procedure is not considered. Another controversial omission is dental procedures, contrasting with the inclusion of dental extraction in other guideline documents on anticoagulant use,2,8,9 including the guidelines of the Spanish College of Dentists.10

Our final concern relates to ophthalmology. The article states that anticoagulation can be maintained during procedures performed under topical anesthesia. However, the preceding section on surgery contraindicates anticoagulation during cataract surgery. Does this then refer only to cataract surgery not performed under topical anesthesia? Other guidelines and manuals include a list of procedures requiring suspension of anticoagulation,2,2,7–9 and this consensus document would have been strengthened by the inclusion of such a practical list.

We would like once again to congratulate the authors on the completion of this consensus document, which we are sure will be consulted and followed by health care professionals in all specialties.


D. Vivas, I. Roldan, R. Ferrandis, et al.
Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU.
Rev Esp Cardiol., 71 (2018), pp. 553-564
J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, et al.
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest., 141 (2012), pp. e326S-e350S
J. Valdivia.
Anticoagulantes orales en el periodo perioperatorio: ¿qué hacemos? Comisión de Antiagregantes y Tratamientos Antitrombóticos.
M.I. Egocheaga, E. Martín Rioboó.
Algoritmos para la práctica clínica en la anticoagulación con dabigatrán.
Jarpyo Editores, (2015),
J.U. Doherty, T.J. Gluckman, W.J. Hucker, et al.
2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: A report of the American College of Cardiology Clinical Expert Consensus Document Task Force.
J Am Coll Cardiol., 69 (2017), pp. 871-898
J. Steffel, P. Verhamme, T.S. Potpara, et al.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin antagonist oral anticoagulants in patients with atrial fibrillation.
Eur Heart J., 39 (2018), pp. 1330-1393
H. Heidbuchel, P. Verhamme, M. Alings, et al.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Europace., 17 (2015), pp. 1467-1507
A.N. Raval, J.E. Cigarroa, M.K. Chung, et al.
Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association.
Circulation., 135 (2017), pp. e604-e633
Consejo de Dentistas. Organización colegial de dentistas de España. Protocolo de seguridad hemostásica de los procedimientos odontológicos en pacientes tratados con anticoagulantes. Available at: Accessed 9 May 2018.
Copyright © 2018. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?